tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

NKGen Biotech Secures Funding Amid Compliance Challenges

Story Highlights
  • NKGen Biotech raised $2 million through a stock purchase agreement with HekaBio K.K.
  • The funding aids NKGen in regaining compliance and supports its NK cell therapy’s entry into the Japanese market.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
NKGen Biotech Secures Funding Amid Compliance Challenges

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

NKGen Biotech ( (NKGN) ) has shared an update.

On July 14, 2025, NKGen Biotech entered into a Stock Purchase Agreement with HekaBio K.K., selling 8 million shares and issuing warrants for an additional 8 million shares, raising $2 million. This funding will help NKGen address reporting compliance issues and listing standards, as their shares move temporarily to the OTC Expert Market due to filing delays. The company is working to regain compliance and aims to uplist to OTCQB and eventually return to Nasdaq or NYSE American. This investment also supports NKGen’s strategic efforts to introduce its NK cell therapy, troculeucel, to the Japanese market, and follows challenges faced due to the bankruptcy of its former parent company, NKMax Co., Ltd.

More about NKGen Biotech

NKGen Biotech is a clinical-stage biotechnology company based in Santa Ana, California, focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics.

Average Trading Volume: 177,061

Technical Sentiment Signal: Sell

Current Market Cap: $13.53M

Learn more about NKGN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1